Peter Hodson International Wex Technologies WXI-T WATCH Mar 09, 2006

WEX Pharmaceutical recently failed its trials. The company now has to regroup and decide what to do next. It is a long process to rebuild. The vice-president stepped down as well recently. Recommends looking at how much cash the company has before entering.

Peter Hodson

Unlock Rating

$0.450

Stock price when the opinion was issued

misc industrial products

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

WAIT

In phase 2 clinical trials in Canada andChina. Trading in a $2/2.50 range. In current negotiations.

Most Recent Experts

Michael Hakes - CFA, MBA

Murray Wealth Group

Daniel Straus

National Bank Financial

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Stan Wong

Private Wealth Management, ScotiaMcleod

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Peter Hodson International Wex Technologies WXI-T WATCH Mar 09, 2006

You might be interested:

International Wex Technologies(WXI-T)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals